IL95153A0 - Novel antigens and their production - Google Patents
Novel antigens and their productionInfo
- Publication number
- IL95153A0 IL95153A0 IL95153A IL9515390A IL95153A0 IL 95153 A0 IL95153 A0 IL 95153A0 IL 95153 A IL95153 A IL 95153A IL 9515390 A IL9515390 A IL 9515390A IL 95153 A0 IL95153 A0 IL 95153A0
- Authority
- IL
- Israel
- Prior art keywords
- protein
- particle
- hepatitis
- residues
- followed
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 abstract 3
- 239000011246 composite particle Substances 0.000 abstract 3
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 102100031673 Corneodesmosin Human genes 0.000 abstract 2
- 229940096437 Protein S Drugs 0.000 abstract 2
- 108010031318 Vitronectin Proteins 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000320412 Ogataea angusta Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534289A | 1989-07-25 | 1989-07-25 | |
| US38918489A | 1989-08-03 | 1989-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL95153A0 true IL95153A0 (en) | 1991-06-10 |
Family
ID=27010975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL95153A IL95153A0 (en) | 1989-07-25 | 1990-07-23 | Novel antigens and their production |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0414374B1 (fr) |
| JP (1) | JP3069907B2 (fr) |
| KR (1) | KR0181940B1 (fr) |
| CN (1) | CN1080304C (fr) |
| AT (1) | ATE159031T1 (fr) |
| AU (3) | AU5972890A (fr) |
| CA (1) | CA2021762C (fr) |
| DE (1) | DE69031556T2 (fr) |
| DK (1) | DK0414374T3 (fr) |
| ES (1) | ES2109921T3 (fr) |
| FI (1) | FI903721A0 (fr) |
| GR (1) | GR3025819T3 (fr) |
| HK (1) | HK1003032A1 (fr) |
| HU (1) | HU216013B (fr) |
| IE (1) | IE902690A1 (fr) |
| IL (1) | IL95153A0 (fr) |
| MA (1) | MA21911A1 (fr) |
| NO (1) | NO304268B1 (fr) |
| NZ (1) | NZ234615A (fr) |
| PL (1) | PL168597B1 (fr) |
| PT (1) | PT94791B (fr) |
| SG (1) | SG48175A1 (fr) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0299242A3 (fr) * | 1987-06-22 | 1989-01-25 | Medico Labs Ag | Particules immunogènes peptiques virales hétérologues |
| PL168408B1 (pl) * | 1989-08-03 | 1996-02-29 | Smithkline Beecham Biolog | Sposób wytwarzania stransformowanego mikroorganizmu PL |
| EP0491077A1 (fr) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques |
| IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
| IL101651A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Hepatitis b virus surface proteins with reduced host carbohydrate content |
| MY111880A (en) * | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
| US6620414B2 (en) | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| ES2334181T3 (es) | 1992-05-23 | 2010-03-05 | Glaxosmithkline Biologicals S.A. | Vacunas combinadas que comprenden antigeno de superficie de la hepatitis b y otros antigenos. |
| ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
| ATE157882T1 (de) * | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| CA2129156A1 (fr) * | 1993-07-30 | 1995-01-31 | Friedrich Dorner | Forte expression d'un polypeptide contenant la region pres1 modifiee de l'antigene de poids moleculaire eleve du virus de l'hepatite b |
| US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| US5658579A (en) * | 1995-07-31 | 1997-08-19 | The Procter & Gamble Company | Cosmetic powder compositions having improved skin coverage |
| GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| KR100372233B1 (ko) * | 1997-03-12 | 2003-06-11 | 주식회사 코리아나화장품 | 미백 파우더, 그의 제조방법 및 그를 함유하는 메이크업 미백 화장료 |
| PL201482B1 (pl) | 1998-10-16 | 2009-04-30 | Smithkline Beecham Biolog | Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki |
| PL349347A1 (en) * | 1999-01-12 | 2002-07-15 | Smithkline Beecham Biolog | Novel treatment |
| FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1648931B1 (fr) | 2003-07-21 | 2011-02-09 | Transgene S.A. | Cytokines multifonctionnelles |
| EP1654283B1 (fr) | 2003-08-13 | 2011-07-13 | Novartis Vaccines and Diagnostics, Inc. | Procede ameliore de purification d'analogues tfpi et tfpi |
| RU2442825C2 (ru) | 2005-04-18 | 2012-02-20 | Новартис Вэксинес Энд Дайэгностикс Инк. | Иммуногенные композиции, способы получения таких композиций и плазмида, включенная в такие композиции |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| PL2097102T3 (pl) | 2006-09-07 | 2012-10-31 | Glaxosmithkline Biologicals Sa | Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| JP5443164B2 (ja) | 2006-09-26 | 2014-03-19 | インフェクティアス ディジーズ リサーチ インスティチュート | 合成アジュバントを含むワクチン組成物 |
| EP2086582B1 (fr) | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccin comprenant une emulsion adjuvante huile en l'eau |
| KR101151202B1 (ko) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 수중유 에멀젼 애주번트를 포함하는 백신 |
| AR066405A1 (es) | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
| AU2008248640A1 (en) | 2007-05-02 | 2008-11-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
| DK2437753T3 (en) | 2009-06-05 | 2016-12-19 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
| CN102038948B (zh) * | 2009-10-10 | 2013-04-10 | 复旦大学 | 一种控制乙型肝炎病毒持续性感染的疫苗 |
| WO2011046218A1 (fr) * | 2009-10-16 | 2011-04-21 | 株式会社カネカ | Levure hansenula polymorpha apte à produire un anticorps, procédé de production d'anticorps la faisant intervenir, et anticorps produit à partir de celle-ci |
| KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| EP3632463A1 (fr) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires |
| CN103087933B (zh) * | 2011-11-08 | 2015-07-22 | 北京生物制品研究所 | 一种重组多形汉逊酵母菌及其制备方法 |
| CN110339160A (zh) | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
| CN102643349B (zh) * | 2012-04-17 | 2013-12-18 | 中国医学科学院医学生物学研究所 | 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备 |
| NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
| WO2014066443A1 (fr) | 2012-10-23 | 2014-05-01 | Emory University | Conjugués de gm-csf et d'il-4, compositions et procédés associés |
| US8957047B2 (en) | 2013-04-18 | 2015-02-17 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| IL310015A (en) | 2013-12-31 | 2024-03-01 | Access To Advanced Health Inst | Formulations will be assembled into a single vial |
| EP3268037B1 (fr) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Agonistes cd27 |
| CN105797151A (zh) * | 2016-03-25 | 2016-07-27 | 汪和睦 | 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗 |
| CN109071665B (zh) | 2016-04-18 | 2022-11-01 | 塞德斯医疗公司 | 结合人cd40的激动性抗体及其用途 |
| KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
| EP3458475B1 (fr) | 2016-05-16 | 2022-07-27 | Access to Advanced Health Institute | Formulation contenant un agoniste de tlr et procédés d'utilisation |
| EP3463300A1 (fr) | 2016-06-01 | 2019-04-10 | Infectious Disease Research Institute | Nanoparticules d'alun contenant un agent d'encollage |
| JP2020524143A (ja) | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| WO2019051149A1 (fr) | 2017-09-08 | 2019-03-14 | Infectious Disease Research Institute | Formulations liposomales comprenant de la saponine et procédés d'utilisation |
| US20210198374A1 (en) | 2018-04-17 | 2021-07-01 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| BR112021023726A2 (pt) | 2019-05-25 | 2022-02-15 | Infectious Disease Res Inst | Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante |
| AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| AU2022253269A1 (en) | 2021-04-09 | 2023-11-23 | Celldex Therapeutics, Inc. | Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof |
| WO2023077521A1 (fr) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Constructions bispécifiques anti-ilt4 et anti-pd-1 |
| WO2024052882A1 (fr) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Composition de vaccin immunogène incorporant une saponine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0288198A3 (fr) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production de peptide |
-
1990
- 1990-07-19 ES ES90307900T patent/ES2109921T3/es not_active Expired - Lifetime
- 1990-07-19 EP EP90307900A patent/EP0414374B1/fr not_active Expired - Lifetime
- 1990-07-19 DE DE69031556T patent/DE69031556T2/de not_active Expired - Fee Related
- 1990-07-19 SG SG1996007620A patent/SG48175A1/en unknown
- 1990-07-19 DK DK90307900.2T patent/DK0414374T3/da active
- 1990-07-19 AT AT90307900T patent/ATE159031T1/de not_active IP Right Cessation
- 1990-07-23 PT PT94791A patent/PT94791B/pt not_active IP Right Cessation
- 1990-07-23 MA MA22181A patent/MA21911A1/fr unknown
- 1990-07-23 IL IL95153A patent/IL95153A0/xx unknown
- 1990-07-23 AU AU59728/90A patent/AU5972890A/en not_active Abandoned
- 1990-07-23 CA CA002021762A patent/CA2021762C/fr not_active Expired - Fee Related
- 1990-07-23 NZ NZ234615A patent/NZ234615A/xx unknown
- 1990-07-24 IE IE269090A patent/IE902690A1/en unknown
- 1990-07-24 NO NO903285A patent/NO304268B1/no not_active IP Right Cessation
- 1990-07-24 FI FI903721A patent/FI903721A0/fi not_active Application Discontinuation
- 1990-07-24 KR KR1019900011386A patent/KR0181940B1/ko not_active IP Right Cessation
- 1990-07-25 PL PL90286209A patent/PL168597B1/pl unknown
- 1990-07-25 CN CN90107172A patent/CN1080304C/zh not_active Expired - Fee Related
- 1990-07-25 JP JP2197578A patent/JP3069907B2/ja not_active Expired - Lifetime
- 1990-07-25 HU HU4615/90A patent/HU216013B/hu not_active IP Right Cessation
-
1994
- 1994-10-28 AU AU77528/94A patent/AU7752894A/en not_active Abandoned
-
1997
- 1997-04-18 AU AU18968/97A patent/AU714652B2/en not_active Ceased
- 1997-12-30 GR GR970403469T patent/GR3025819T3/el unknown
-
1998
- 1998-03-13 HK HK98102133A patent/HK1003032A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL95153A0 (en) | Novel antigens and their production | |
| KR880009130A (ko) | 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원 | |
| DE3280284D1 (de) | Herstellung von oberflaechen-hepatitis-b-antigen in hefe. | |
| EP0175261A3 (en) | Hybrid particle immunogens hybrid particle immunogens | |
| GR3023985T3 (en) | Expression of hepatitis B S and preS2 proteins in methylotrophic yeasts | |
| EP0401941A3 (fr) | Antigène de surface du virus de l'hépatite B, et sa production | |
| EP0134242A4 (fr) | Antigene de peptide protecteur. | |
| EP0250253A3 (fr) | Epitopes de cellules T et B de la région pré-S de l'antigène de surface de l'hépatite B | |
| EP0174444A3 (en) | Hepatitis surface antigen particle vaccine | |
| MY106731A (en) | Novel antigens and methods therefor | |
| EP0864649A3 (fr) | Méthode de préparation de l'antigène de surface de l'hepatite B avec une capacité immunogénique supérieure et utalisation d'une préparation de vaccin | |
| DE2961060D1 (en) | Antigenic composition useful as a vaccine or vaccine intermediate, and process for preparing same | |
| EP1274851A4 (fr) | Construction d'acide nucleique codant un constituant de traitement derive de la region n-terminale de orf2 du virus de l'hepatite, et polypeptide antigenique | |
| EP0503252A3 (en) | Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines | |
| ATE53235T1 (de) | Synthese von menschlichen viralen antigenen mit hilfe von hefe. |